On 23 Oct 2026, JUNSHI BIO (01877.HK) dosed the first patient in a 282-patient Phase III trial of JS203 plus chemo in r/r DLBCL.
On 23 Oct 2026, ZAI LAB (09688.HK) reported an 81.8% confirmed ORR and 81.9% six-month PFS rate for zoci plus atezolizumab in first-line ES-SCLC patients.
On October 23, 2026, the HSTECH rose 2.05% and the HSI gained 0.69%. MINIMAX-W led AI concept stocks with a 16.74% gain, while BLACK SESAME fell 3.87%.
IMPACT THERAP-B(07630.HK) presented senaparib, IMP1734 and IMP1707 data at ESMO 2026, with the FLAMES study showing median PFS of 38.7 versus 13.6 months (HR 0.47).
On October 23, 2026, BIDU-W (09888.HK) trended higher in the afternoon session. As of 14:21, it was quoted at HK$76.25, up 1.53%.
ASMPT (00522.HK) fell 2.03% to HKD 120.600; NVIDIA signed a USD 1.3 billion packaging deal with Amkor and is expanding capacity with supply chain partners.
XIAOMI-W (01810.HK) rose 4.03% to HKD 26.840; the World Physical AI Conference was held, and Changde opened 1,658 embodied AI data collection scenarios.
On 23 October 2026, ASCLETIS (01672.HK) said partner Sagimet dosed the first patient in US phase III trial AURORA of denifanstat for moderate-to-severe acne.
On 23 October 2026, CSPC PHARMA (01093.HK) said NMPA approved batoclimab injection as an add-on for AChR antibody-positive generalised myasthenia gravis.
On 23 October 2026, TENNOR THERAP (06872.HK) dosed the first patient in a phase IIb trial of TNP-2092 given into the joint for prosthetic joint infection.
On 22 Oct 2026, HENGRUI PHARMA (01276.HK) won NMPA approval for a Phase III prostate cancer trial of rezvilutamide with ADT after surgery or radiotherapy.
On 22 Oct 2026, XUNFEIHEALTH (02506.HK) released Spark Medical LLM V3.7, topping Shanghai AI Laboratory's MedBench agent evaluation with a 99.6 score.
On 22 Oct 2026, CSPC PHARMA (01093.HK) launched a China Phase III trial of SYS6043, a B7-H3 ADC, in first-line recurrent or metastatic TNBC.
On 22 Oct 2026, CSPC PHARMA (01093.HK) launched a China Phase II trial of SYH2066 tablets, a small-molecule RSV fusion protein inhibitor, for RSV infection.
On 22 Oct 2026, BOAN BIOTECH (06955.HK) said the first patient enrolled in the China Phase I study of BA1203, its masked PD-1/IL-2 antibody-cytokine prodrug.
On October 22, the HSTECH fell 5.03% to 3,793.93 and the HSI lost 3.03%; all 20 AI concept stocks closed lower, BIRENTECH down 10.56%, TENCENT off 2.89%.
